Chikungunya Vaccine Trials Begin

A phase 1 and 2 clinical trial of anexperimental vaccineagainst the viral disease chikungunya has begun enrolling a planned 180 healthy adult volunteers aged 18 to 45 years with funding by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine, known as MV-CHIKV, is a recombinant live-attenuated measles vaccine virus expressing chikungunya proteins that induce antibody production.
Source: JAMA - Category: General Medicine Source Type: research